PERJETA (pertuzumab)
ANTINEOPLASTIC - EGF RECEPTOR 2 (HER2) SUBDOMAIN II BLOCKER · HER2-POSITIVE CARCINOMA OF BREAST
GENENTECH
Drug class
Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker
The therapeutic classification "Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker" represents a specialized group of targeted antineoplastic monoclonal antibodies, clinically typified by pertuzumab. Read more about Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker
2 drugs in this class 1 manufacturers
Drugs in Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker
PHESGO (pertuzumab-trastuzumab-hyaluronidase-zzxf)
ANTINEOPLASTIC - HER2 INHIBITORS · HER2-POSITIVE CARCINOMA OF BREAST
GENENTECH
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker preselected. Add indication or manufacturer filters there.
The therapeutic classification "Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker" represents a specialized group of targeted antineoplastic monoclonal antibodies, clinically typified by pertuzumab.
Agents in this class specifically bind to the extracellular dimerization domain—subdomain II—of the human epidermal growth factor receptor 2 (HER2) protein.
By sterically inhibiting ligand-dependent heterodimerization of HER2 with other HER family receptors (particularly HER3), these agents arrest downstream intracellular oncogenic signaling cascades, including the MAPK and PI3K/Akt pathways, while also mediating antibody-dependent cellular cytotoxicity.
They are primarily indicated, frequently in synergistic combination with subdomain IV-directed therapies like trastuzumab and chemotherapy, for the treatment of HER2-overexpressing early and metastatic breast cancers.
-
fda.gov
The therapeutic classification "Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker" represents a specialized group of targeted antineoplastic monoclonal antibodies, clinically typified by pertuzumab Agents in this class specifically bind to the extracellular dimerization domain—subdomain II—of the human epidermal growth factor receptor 2 (HER2) protein By sterically inhibiting ligand-dependent heterodimerization of HER2 with other HER family receptors (particularly HER3), these agents a...
-
fda.gov
The therapeutic classification "Antineoplastic - EGF Receptor 2 (HER2) Subdomain II Blocker" represents a specialized group of targeted antineoplastic monoclonal antibodies, clinically typified by pertuzumab
-
perjeta-hcp.com
By sterically inhibiting ligand-dependent heterodimerization of HER2 with other HER family receptors (particularly HER3), these agents arrest downstream intracellular oncogenic signaling cascades, including the MAPK and PI3K/Akt pathways, while also mediating antibody-dependent cellular cytotoxicity
-
nih.gov
By sterically inhibiting ligand-dependent heterodimerization of HER2 with other HER family receptors (particularly HER3), these agents arrest downstream intracellular oncogenic signaling cascades, including the MAPK and PI3K/Akt pathways, while also mediating antibody-dependent cellular cytotoxicity They are primarily indicated, frequently in synergistic combination with subdomain IV-directed therapies like trastuzumab and chemotherapy, for the treatment of HER2-overexpressing early and metastat...
-
fda.gov
By sterically inhibiting ligand-dependent heterodimerization of HER2 with other HER family receptors (particularly HER3), these agents arrest downstream intracellular oncogenic signaling cascades, including the MAPK and PI3K/Akt pathways, while also mediating antibody-dependent cellular cytotoxicity
-
pharmacytimes.com
They are primarily indicated, frequently in synergistic combination with subdomain IV-directed therapies like trastuzumab and chemotherapy, for the treatment of HER2-overexpressing early and metastatic breast cancers
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.